Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their ...

Dassault Systèmes is the world leader in mechanical computer-aided design software. Its high-end CAD software, Catia, is the industry standard in automotive, aerospace, and industrial products while ...

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled ...

PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea Inc. (Althea), a U.S.-based sterile fill-finish ...

Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on ...

PCI Pharma Services, (“PCI”)a leading global contract development and manufacturing ...

South African global pharmaceutical giant Aspen Pharmacare has found itself caught in Trump tariff-related market volatility, ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.

Smith, Head of Business Development, Douglas CDMO, touts the advantages of and dispels misconceptions about mid-sized CDMOs.

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...